Synergy IB Investment

RnH-Bio is a biotechnology company that develops exosome-based products for various healthcare applications.

Eastech is a company that specializes in the research and development of drug substance candidates using 3D structural information analysis.

Cigro is a company that offers a data integration solution tailored for e-commerce operators. It operates a performance management platform that automatically gathers data by connecting various sales and advertising channels. This platform presents the collected information in a user-friendly dashboard, allowing businesses to access daily reports and performance notifications. By streamlining data collection and reporting, Cigro enables e-commerce operators to make informed decisions based on comprehensive insights into their performance metrics.

SOS Lab is a company specializing in the development and manufacturing of LiDAR technology, which utilizes lasers to measure distances and shapes in the surrounding environment. The company focuses on creating innovative solutions for self-driving vehicles, featuring its hybrid LiDAR system, the SL-1, which merges motor scanning systems with solid-state MEMS mirrors. This system aims to reduce costs and enhance accessibility in the autonomous vehicle market. In addition to the SL-1, SOS Lab offers the GL-3 for factory automation and robotics, and the TL-3 for security applications. The company is also advancing its technology by integrating hardware sensors with AI-based object recognition, leveraging 3D point cloud data for improved tracking and recognition. To further its mission, SOS Lab collaborates with partners in the automotive electronics sector and global semiconductor companies, with R&D centers in Seoul and Gwangju and business operations in Silicon Valley to expand its presence in the global self-driving and advanced driver-assistance systems markets.

LyseNTech is a biotechnology company focused on combating antibiotic-resistant bacteria through the development of innovative treatments. The company specializes in creating antibiotics derived from bacteriophages, which are viruses that specifically target and eliminate bacteria. Additionally, LyseNTech is engaged in the development of phage-derived endolysins and oncolytic bacteriophages, which are designed to deliver targeted anticancer therapies. This approach allows for the precise targeting and destruction of cancer cells, offering potential advancements in cancer treatment. By harnessing the unique properties of bacteriophages, LyseNTech aims to address critical challenges in both antibiotic resistance and cancer therapy.

Study Senior offers an application-based platform focused on school discovery, facilitating educational assistance for parents and students. The platform features promotional videos, images, and detailed information about various schools, including location and reviews. It also provides solutions for automatic call connections, enabling seamless communication between prospective students and schools. By combining online resources with offline interactions, Study Senior aims to simplify the school selection process, helping families make informed decisions regarding education.

Larchive monitors import and export supply chains for risk management through its intelligence services.

Rznomics is a biotechnology company founded by professor Lee Sung-wook's lab, focusing on the development of innovative gene therapy products aimed at treating liver cancer and other serious medical conditions. The company specializes in ribonucleic acid-based therapies that address significant unmet medical needs, particularly in the areas of cancer, degenerative neurological disorders, and hereditary diseases. By creating new biopharmaceuticals, Rznomics aims to provide medical practitioners with effective treatment options for challenging health issues, including various types of cancer and Alzheimer’s disease. The company has garnered recognition for its technological excellence, having been selected for the TIPS program, which highlights its commitment to advancing medical science.

CK Regeon is a biotechnology company focused on improving human health through the development of innovative drugs. The company specializes in creating small molecules and peptides aimed at treating metabolic disorders, including obesity, diabetes, and non-alcoholic steatohepatitis. Additionally, CK Regeon is dedicated to promoting hair growth and enhancing wound healing, utilizing target-specific compounds that enable medical practitioners to effectively address these health issues.

HUINNO, Inc., founded in 2014 and headquartered in Boston, Massachusetts, develops healthcare devices that monitor vital health data, including blood pressure, heart rate, electrocardiogram (ECG), and blood oxygen saturation levels (SpO2). The company leverages proprietary technologies in wearable devices and artificial intelligence to provide healthcare providers with an effective remote patient monitoring solution aimed at improving the management of chronic cardiac diseases. HUINNO's clinically-tested platform delivers real-time measurements with clinical-grade accuracy and offers an application and cloud-based ecosystem for longitudinal analysis of health trends, medication compliance, and lifestyle habits. This comprehensive approach not only enhances patient care but also aids healthcare professionals in making informed medical decisions while treating conditions such as arrhythmia and hypertension. With additional offices in New York and Seoul, HUINNO is committed to transforming the way clinicians and patients manage chronic health issues.

SnackFever Inc., founded in 2015 and based in Los Angeles, California, specializes in delivering a variety of snacks, candies, drinks, ramen products, and other treats from Korea on a subscription basis in the United States. The company focuses on providing a unique culinary experience by offering monthly deliveries that cater to fans of Korean culture and cuisine. Through its offerings, SnackFever aims to connect with the global Hallyu community, delivering not just food items, but also a sense of enjoyment and cultural engagement.

Rznomics is a biotechnology company founded by professor Lee Sung-wook's lab, focusing on the development of innovative gene therapy products aimed at treating liver cancer and other serious medical conditions. The company specializes in ribonucleic acid-based therapies that address significant unmet medical needs, particularly in the areas of cancer, degenerative neurological disorders, and hereditary diseases. By creating new biopharmaceuticals, Rznomics aims to provide medical practitioners with effective treatment options for challenging health issues, including various types of cancer and Alzheimer’s disease. The company has garnered recognition for its technological excellence, having been selected for the TIPS program, which highlights its commitment to advancing medical science.

Enfusion is a developer of mobile and PC games

HUINNO, Inc., founded in 2014 and headquartered in Boston, Massachusetts, develops healthcare devices that monitor vital health data, including blood pressure, heart rate, electrocardiogram (ECG), and blood oxygen saturation levels (SpO2). The company leverages proprietary technologies in wearable devices and artificial intelligence to provide healthcare providers with an effective remote patient monitoring solution aimed at improving the management of chronic cardiac diseases. HUINNO's clinically-tested platform delivers real-time measurements with clinical-grade accuracy and offers an application and cloud-based ecosystem for longitudinal analysis of health trends, medication compliance, and lifestyle habits. This comprehensive approach not only enhances patient care but also aids healthcare professionals in making informed medical decisions while treating conditions such as arrhythmia and hypertension. With additional offices in New York and Seoul, HUINNO is committed to transforming the way clinicians and patients manage chronic health issues.

AptaBio Therapeutics Inc. is a pharmaceutical biotechnology company based in Yongin-Si, South Korea, that specializes in the discovery and development of selective inhibitors targeting the NOX family of enzymes, as well as aptamer-based anti-cancer drugs. The company's product offerings include a range of transfection reagents designed for DNA or RNA delivery into eukaryotic cells. AptaBio is advancing several product candidates aimed at addressing significant health issues, including PX-115 for diabetic nephropathy, APX-1004 for diabetic retinopathy, and APX-311 for non-alcoholic steatohepatitis (NASH). Founded in 2009, AptaBio Therapeutics focuses on creating innovative solutions for complex medical challenges.

Neuroventi specializes in creating customized solutions and therapies for brain development disorders. The company focuses on developing treatments for conditions such as autism spectrum disorder and attention deficit hyperactivity disorder by targeting specific molecular processes. In addition to its therapeutic offerings, Neuroventi provides drug discovery services centered on natural products, aiming to assist medical professionals in effectively treating and preventing various neurological disorders. With a commitment to advancing the understanding and management of brain health, Neuroventi seeks to enhance cognitive function and overall well-being.